Matthew S. Schwartz
Matthew S. Schwartz is a reporter with NPR's news desk. Before coming to NPR, Schwartz worked as a reporter for Washington, DC, member station WAMU, where he won the national Edward R. Murrow award for feature reporting in large market radio. Previously, Schwartz worked as a technology reporter covering the intricacies of Internet regulation. In a past life, Schwartz was a Washington telecom lawyer. He got his J.D. from Georgetown University Law Center, and his B.A. from the University of Michigan ("Go Blue!").
-
The new strain, which likely originated in the U.K. in September, has spread to more than 30 countries across several continents. Meanwhile, the U.S. saw record COVID-19 deaths in December.
-
"Knucksie," as he was known, pitched the most games of any Braves pitcher. He retired at 48 years old in 1987.
-
Authorities revealed that DNA testing shows the man believed to be the perpetrator of the Christmas Day incident died in the blast.
-
The official moniker, announced by Vice President Pence at a White House ceremony, comes one year after the creation of the newest military branch. The name drew raised eyebrows online.
-
The Trump campaign and allied Republicans had sought to overturn results in six states. "We don't need courts," Rudy Giuliani told Fox News, arguing state lawmakers can just declare Trump the winner.
-
President Trump said on Twitter that his personal attorney, Rudy Giuliani, had tested positive for the coronavirus.
-
Wilton Gregory, the archbishop of Washington, D.C., is among 13 church leaders elevated to cardinal at a ceremony at the Vatican on Saturday.
-
The technology entrepreneur made his fortune in the heyday of the dot-com era, before pivoting to lead the online shoe company — despite knowing little about shoes.
-
The court overturned a Justice Department decision denying the asylum of a former Colombia police officer who received multiple death threats from the Revolutionary Armed Forces of Colombia.
-
The experimental cocktail from the biotech company Regeneron is the same drug President Trump got when he was battling the coronavirus this year. It is designed for mild to moderate cases.